8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 17, 2026·SEC
Material company update
Apr 9, 2026·SEC
Theriva Biologics, Inc.(TOVX)Earnings, Financials & Key Ratios
TOVX•AMEX
$0.24
Price updated Jul 7, 2026
AboutTheriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.Show more
- Revenue$0
- EBITDA-$15M+43.1%
- Net Income-$25M+1.6%
- EPS (Diluted)-2.08+89.1%
- ROE-146.58%-67.9%
TOVX Price & Volume
Theriva Biologics, Inc. (TOVX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Generation Potential
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and dilution risk
Key Thesis Takeaways
- Theriva Biologics remains a high-risk, clinical-stage entity characterized by persistent operational deficits and a reliance on external financing to sustain its R&D pipeline.
- While the company recorded a nominal $300,000 in revenue during 2026Q1, the lack of a recurring commercial model suggests that long-term viability is tethered to the success of its oncolytic virus assets.
- Investors should monitor the $19.6 million in goodwill and the ongoing erosion of shareholder equity, which has declined from $39.7 million in 2023Q4 to $15.4 million in 2026Q1, as these factors indicate significant potential for further dilutive capital raises.
Verdict Logic
the company's precarious financial position is underscored by a $360.8 million accumulated deficit in retained earnings and a limited cash reserve of only $14.4 million as of 2026Q1.
TOVX Growth Metrics
Theriva Biologics, Inc. (TOVX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM13.52%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM87.77%
Return on Capital
10 Years-141%
5 Years-46.58%
3 Years-53.53%
Last Year-53.65%
TOVX Recent Earnings
Theriva Biologics, Inc. (TOVX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.05+0.0%
$0.05
Rev
$300,000
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$1.85+525.3%
$0.43
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.45-18.4%
$0.38
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$1.93-407.9%
$0.38
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.05vs $0.05+0.0% | $300,000 |
| Q2 2026 | Mar 12, 2026 | $1.85vs $0.43+525.3% | — |
| Q4 2025 | Nov 12, 2025 | $0.45vs $0.38-18.4% | — |
| Q3 2025 | Aug 11, 2025 | $1.93vs $0.38-407.9% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Theriva Biologics, Inc. (TOVX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.24 | $8.4M | -0.11 | — | — | -146.58% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $15.63 | $1.31B | -29.49 | — | — | -38.92% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $0.45 | $65.98M | -1.54 | 31.28% | -998.18% | -84.55% | — |
Compare TOVX vs Peers
Theriva Biologics, Inc. (TOVX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TOVX SEC Filings & Documents
Theriva Biologics, Inc. (TOVX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TOVX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TOVX Frequently Asked Questions
Theriva Biologics, Inc. (TOVX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Theriva Biologics, Inc.'s revenue?
Theriva Biologics, Inc. (TOVX) reported $0.3M in revenue for fiscal year 2025. This represents a 200% increase from $0.1M in 1994.
Is TOVX profitable?
Theriva Biologics, Inc. (TOVX) reported a net loss of $21.5M for fiscal year 2025.
Dividend & Returns
What is TOVX's return on equity?
Theriva Biologics, Inc. (TOVX) has a return on equity (ROE) of -146.6%. Negative ROE indicates the company is unprofitable.
What is Theriva Biologics, Inc.'s free cash flow?
Theriva Biologics, Inc. (TOVX) had negative free cash flow of $14.4M in fiscal year 2025, likely due to heavy capital investments.